Stock Movers: Novo Nordisk Falls, Puma Executive Exit, Trainline Surges
Market movers: Novo Nordisk slides on Morgan Stanley downgrade; Puma’s CCO to leave; Trainline jumps after strong H1 trading update and £100m buyback.
Editorial companion
What stands out
Bloomberg's rundown captures three different investor moments in one episode. Novo Nordisk slid as much as 2% on Tradegate after Morgan Stanley downgraded the obesity drug giant, arguing the stock's premium may not price in subdued mid-term growth. Puma's Chief Commercial Officer (CCO), Matthias Baeumer, will exit the management board on Sept. 30, a reminder that leadership changes can unstick execution-sensitive consumer names.